Molecular Net Tangible Assets from 2010 to 2024

MOLN Stock  USD 3.87  0.16  4.31%   
Molecular Partners Net Tangible Assets yearly trend continues to be very stable with very little volatility. Net Tangible Assets are likely to grow to about 283.6 M this year. Net Tangible Assets is the total assets of Molecular Partners AG minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2010-12-31
Previous Quarter
270.1 M
Current Value
283.6 M
Quarterly Volatility
67.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 46.5 K or Selling General Administrative of 12.2 M, as well as many exotic indicators such as Price To Sales Ratio of 18.47, Dividend Yield of 0.0 or PTB Ratio of 0.62. Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
  
This module can also supplement various Molecular Partners Technical models . Check out the analysis of Molecular Partners Correlation against competitors.

Latest Molecular Partners' Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Molecular Partners AG over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Molecular Partners' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Molecular Net Tangible Assets Regression Statistics

Arithmetic Mean138,719,731
Geometric Mean126,624,423
Coefficient Of Variation48.34
Mean Deviation49,666,769
Median116,702,000
Standard Deviation67,056,312
Sample Variance4496.5T
Range230.3M
R-Value0.59
Mean Square Error3180.5T
R-Squared0.34
Significance0.02
Slope8,784,112
Total Sum of Squares62951.7T

Molecular Net Tangible Assets History

2024283.6 M
2023270.1 M
2022234.9 M
2021107 M
2020106.9 M
201953.4 M
201891.3 M

About Molecular Partners Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Molecular Partners income statement, its balance sheet, and the statement of cash flows. Molecular Partners investors use historical funamental indicators, such as Molecular Partners's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Molecular Partners investors may use each financial statement separately, they are all related. The changes in Molecular Partners's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Molecular Partners's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Molecular Partners Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Molecular Partners. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Tangible Assets270.1 M283.6 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:
Check out the analysis of Molecular Partners Correlation against competitors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Molecular Stock analysis

When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.215
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.17)
Return On Equity
(0.30)
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.